Lucid Diagnostics Inc
LUCD
Company Profile
Business description
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Contact
360 Madison Avenue
25th Floor
New YorkNY10017
USAT: +1 917 813-1828
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
82
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
We think the new profit target is aggressive and unlikely to be met.
stocks
7 undervalued US stocks that crushed earnings
Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks
Undervalued ASX share hitting on all cylinders
Strong performance across all segments in latest earnings release.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,008.00 | 157.40 | -1.72% |
| CAC 40 | 8,352.00 | 16.91 | -0.20% |
| DAX 40 | 26,598.64 | 151.31 | -0.57% |
| Dow JONES (US) | 51,608.17 | 739.38 | -1.41% |
| FTSE 100 | 10,881.55 | 21.01 | -0.19% |
| HKSE | 23,578.65 | 175.19 | -0.74% |
| NASDAQ | 24,509.76 | 626.52 | -2.49% |
| Nikkei 225 | 58,956.67 | 705.35 | -1.18% |
| NZX 50 Index | 14,350.68 | 46.91 | 0.33% |
| S&P 500 | 7,416.59 | 145.08 | -1.92% |
| S&P/ASX 200 | 8,892.00 | 152.70 | -1.69% |
| SSE Composite Index | 3,591.89 | 10.68 | -0.30% |